| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| Cost of Revenue | $684K | — |
| R&D Expense | $10.6M | — |
| SG&A Expense | $10.6M | — |
| Operating Income | -$21.9M | — |
| Pre-tax Income | -$25.3M | — |
| Income Tax | $0 | — |
| Net Income | -$25.1M | — |
| EPS (Basic) | -$1.51 | — |
| EPS (Diluted) | -$1.51 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $17.1M | -16.9% |
| Accounts Receivable | $35K | +0.0% |
| Inventory | $1.7M | -34.8% |
| Current Assets | $20.1M | -20.8% |
| Total Assets | $43.3M | -10.7% |
| Current Liabilities | $8.2M | +6.1% |
| Long-term Debt | $21.0M | +30.9% |
| Total Liabilities |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$19.0M | — |
| Capital Expenditures | $374K | — |
| Investing Cash Flow | -$374K | — |
| Financing Cash Flow | $16.1M | — |
| Free Cash Flow | -$19.4M | — |
| $30.9M |
| +8.1% |
| Stockholders' Equity | $12.4M | -37.7% |